Marieke van Rosmalen

Clinical outcomes in MMN 37 2 REFERENCES 1. Goedee HS, Jongbloed BA, van Asseldonk J-TH, et al. A comparative study of brachial plexus sonography and magnetic resonance imaging in chronic inflammatory demyelinating neuropathy and multifocal motor neuropathy. Eur. J. Neurol. 2017;24:1307–1313. 2. Vlam L, Van Der Pol WL, Cats EA, et al. Multifocal motor neuropathy: Diagnosis, pathogenesis and treatment strategies. Nat. Rev. Neurol. 2012;8:48–58. 3. VanAsseldonk J, Franssen H, Van Den Berg-Vos R, et al. Multifocal motor neuropathy. Lancet Neurol. 2005;4:309–319. 4. Goedee HS, Van Der Pol WL, Van Asseldonk JTH, et al. Diagnostic value of sonography in treatment-naive chronic inflammatory neuropathies. Neurology 2017;88:143–151. 5. Van Schaik IN, Léger JM, Nobile-Orazio E, et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of multifocal motor neuropathy. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society - First revis. J Peripher Nerv Syst 2010;15:295–301. 6. van Schaik I, van den Berg L, de Haan R, Vermeulen M. Intravenous immunoglobulin for multifocal motor neuropathy. Cochrane Database Syst. Rev. 2005;2:920–921. 7. Léger JM, Chassande B, Musset L, et al. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain 2001;124:145– 153. 8. Eftimov F, Vermeulen M, De Haan RJ, et al. Subcutaneous immunoglobulin therapy for multifocal motor neuropathy. J. Peripher. Nerv. Syst. 2009;14:93–100. 9. HarboT,AndersenH, HessA, et al. Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: A randomized, single-blinded cross-over trial. Eur. J. Neurol. 2009;16:631–638. 10. Markvardsen LH, Harbo T. Subcutaneous immunoglobulin treatment in CIDP and MMN. Efficacy, treatment satisfaction and costs. J. Neurol. Sci. 2017;378:19–25. 11. Cats E, van der Pol WL, Piepers S, et al. Correlates of outcome and response to IVIG in 88 patients with multifocal motor neuropathy. Neurology 2011;75:818–825. 12. Lange D, Weimer L, Trojaborg W, et al. Multifocal motor neuropathy with conduction block: slow but not benign. Arch Neurol 2006;63:1778–1781. 13. Van den Berg-Vos RM, Franssen H, Visser J, et al. Disease severity in multifocal motor neuropathy and its association with the response to immunoglobulin treatment. J. Neurol. 2002;249:330–336. 14. Taylor B V., Wright RA, Harper CM, Dyck PJ. Natural history of 46 patients with multifocal motor neuropathy with conduction block. Muscle and Nerve 2000;23:900–908. 15. VanAsseldonk JTH, Van Den Berg LH, Kalmijn S, et al. Axon loss is an important determinant of weakness in multifocal motor neuropathy. J. Neurol. Neurosurg. Psychiatry 2006;77:743– 747. 16. Vanhoutte EK, Faber CG, Van Nes SI, et al. Rasch-built Overall Disability Scale for Multifocal motor neuropathy (MMN-RODS©). J. Peripher. Nerv. Syst. 2015;20:296–305. 17. Merkies ISJ, Schmitz PIM. Getting closer to patients: the INCAT Overall Disability Sum Score relates better to patients’ own clinical judgement in immune-mediated polyneuropathies. J. Neurol. Neurosurg. Psychiatry 2006;77:970–972. 18. Nes S Van, Vanhoutte E, van Doorn P, et al. Rasch-built Overall Disability Scale (R-ODS) for immune-medicated peripheral neuropathies. Int. Classif. 2011;76:337–345. 19. Rietberg MB, Van Wegen EEH, Kwakkel G. Measuring fatigue in patients with multiple sclerosis: reproducibility, responsiveness and